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Infectious laryngotracheitis (ILT) is a highly contagious acute respiratory disease 
of chickens for which safe and efficacious vaccines are not available currently. In the 
present study, we have generated three recombinant Newcastle disease viruses (rNDV’s) 
expressing three major envelope glycoproteins gB, gC and gD of ILTV individually.                                                                     
A single oculonasal inoculation of chickens with rNDV’s elicited detectable level of 
systemic antibodies specific to ILTV. Following challenge with virulent strain of ILTV, 
chickens immunized with the rNDV’s displayed partial protection with reduced clinical 
signs and shorter duration of disease compared to the control group. Our data suggested 
that NDV vectored ILTV vaccines are useful against ILTV infection, but might require 
augmentation by a second dose or require modification of ILTV glycoproteins which 
allow them to incorporate into the mature rNDV virions for better induction of humoral 
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Chapter 1: General introduction 
 
1.1 Introduction 
Infectious laryngotracheitis (ILT) is an acute respiratory disease of chickens, 
which is caused by infectious laryngotracheitis virus (ILTV), a member of the family 
herpesviridae.  The disease is characterized by signs of respiratory depression, gasping, 
expectoration of blood, mucus, and high mortality [1].  The disease occurs worldwide and 
varies in severity from mild respiratory disease to severe outbreaks with mortality as high 
as 70% [1].  Although the exact economic losses due to ILT is not known, the poultry 
industry of the United States experiences multi‐million dollar losses each year as a result 
of ILTV ‐induced mortality, delayed growth, and decreased egg production. 
     Currently, live‐attenuated vaccines are used to control ILTV infections.  
However, these vaccines are not satisfactory.  The live‐attenuated vaccines, particularly 
the Chick Embryo Origin (CEO),  have several disadvantages: (i) reversion to virulence 
after bird‐to‐bird passage  [2];  (ii)  induction  of  latent  infection  [3];  (iii)  insufficient  
attenuation  [4];  and  (iv) difficulty  to  distinguish  the  immune  response  induced  by  
vaccination  from  that  by  field infection [5].   Therefore, there is a need to develop a 
safer vaccine to control and possibly eradicate ILT.  A recombinant viral vector vaccine 
incorporating gene(s) for ILTV immunogens could fulfill these requirements. However, 






 It has been shown that vaccination with herpes virus envelope glycoproteins can 
induce protective immunity [6]. There are eleven glycoproteins in the envelope of ILTV 
[7]. A subunit vaccine containing glycoprotein B (gB) protected 100% of chickens 
against clinical disease and also against viral replication [8, 9], indicating that it is a 
major protective immunogen of ILTV. However, the role of other major envelope 
glycoproteins, such as gC and gD, in protection and immunity has not been evaluated. 
 In this study, we have used Newcastle disease virus (NDV) as a vector to express 
the immunogenic protein(s) of ILTV. We hypothesize that recombinant NDV (rNDV) 
expressing the envelope glycoprotein(s) of ILTV would provide complete protection to 
chickens from virulent ILTV challenge. Several characteristics of NDV suggest that a 
rNDV expressing envelope glycoprotein(s) of ILTV would be a very good vaccine 
candidate.  NDV strain LaSota is widely used as a vaccine with a proven track record of 
efficacy and safety.  NDV naturally enters via the respiratory tract and therefore, elicits 
mucosal immunity at the respiratory tract, the portal of entry for ILTV.   NDV elicits 
strong humoral and cellular immune responses.   NDV replicates in the cytoplasm of 
infected cells and does not undergo genetic recombination, which makes the expression 
vector stable and safe.   NDV is a relatively small virus with six genes; therefore, chances 
are better for a lack of significant immune competition between engineered ILTV antigen 
and NDV‐specific antigens. 
 Our laboratory has developed a reverse genetics system to produce infectious 
rNDV strain LaSota from cloned cDNAs [10]. This system has been successfully used to 
express several foreign antigens [11‐18].  Therefore,  the  reverse  genetics  system  for 




 In the present study, we have investigated the individual contributions of three 
important envelope glycoproteins of ILTV (gB, gC, and gD) in protection and immunity.  
In herpes simplex virus, gC mediates attachment of virions to cells, while gB and gD are 
essential for attachment and entry of virus into the cell [19‐21]. The gB has been shown 
to be a major protective immunogen of ILTV [22], but the roles of gC and gD have not 
been determined.  In closely related human and animal herpes viruses, gB, gC, and gD 
have been shown to be the major protective immunogens [6, 23, 24].  Therefore, the 
overall objective of this study is to determine theroles of these three ILTV glycoproteins 
in protection and immunity.   
1.2 Research objectives 
The specific objectives in the present study on NDV vectored ILTV vaccines are: 
1. Constructions of recombinant NDV strain LaSota cDNAs containing gB, gC, and 
gD genes of ILTV. 
2. Recovery and characterization of recombinant NDVs containing gB, gC and gD 
genes of ILTV.    
3. Evaluation of immunogenicity and protective efficacy of recombinant NDVs 










Chapter 2: Literature review 
 
2.1 Infectious laryngotracheitis virus (ILTV) 
ILTV is a member of the genus Iltovirus within the subfamily alphaherpesvirinae 
of the family herpesviridae [1, 25]. The virion varies in size from 150‐250nm. A mature 
ILTV particle consists of a core  containing a linear double‐stranded DNA, an icosahedral 
capsid containing 162 capsomers,  an  amorphous  material  that  surrounds  the  capsid  
and  is  designated  the tegument, and an envelope c ntaining viral glycoproteins [25]. 
The ILTV genome sequence has been assembled from sequenced regions of different 
strains resulting in a total of 148,687 nucleotides with 77 open reading frames (ORF) 
predicted to be translated into 73 different proteins [26]. However, the genome size of 
ILTV may vary depending on strains and/or passage history [27]. The ILTV DNA has a 
guanine plus cytosine ratio of 45% [25]. The genome is arranged into unique long (UL) 
and unique short (US) regions bounded by terminal repeats (TR) and inverted repeats 
(IR) (Fig.1.). 
 In virions, the ILTV genome exists predominantly in two different isometric 
forms. In 50% of virion genomes, the US region is directed in one orientation and it 
exists in the opposite orientation in the remaining 50% of the genomes. In ILTV, the UL 
region is 113kb and the US region is 13kb. ILTV strains are antigenically homogenous 
based on virus neutralization and cross protection studies [28]. However, minor antigenic 







Fig.1. Map of the double‐stranded DNA genome of ILTV (150 kbp) [25]. 
 
In herpesviruses, the glycoproteins on the surface of nvelope are the primary 
inducers and   targets   of   the   humoral   and   cell   mediated   immune   (CMI)   
responses   [6].   Eleven glycoproteins (gB, gC, gD, E, gG, gH, gI, gJ, gK, gL and gM) 
have been identified on the envelope of ILTV and most f these glycoproteins are 
conserved in Alphaherpesviruses [25]. A subunit ILTV vaccine made of a 205 KDa 
complex containing gB protected 100% of chickens [8, 9], indicating that gB is a major 
protective immunogen. The role of other ILTV glycopr teins in immunity   and   
protection   has   not   been   evaluated.   However,   ILTV   glycoproteins   have 
homologous glycoproteins in other herpesviruses where their functions are known.  For 
example, in  herpes  simplex virus (HSV) it was found gB, gC, gD, gE and gI induced 
highest neutralizing  titers  and  protective  immunity  [6].  In  Pseudorabies  virus  (Prv),  
gC  has  been identified  as  a  major  target  of  neutralizing  antibody  [30‐33]  and  
T‐cell  mediated  immune responses [34, 35]. Neutralizing antibodies have also been 




 In  bovine  herpesvirus‐1  (BHV‐1),  gB,   gC  and  gD  are  effective immunogens ad
can protect calves from virulent field challenge [36‐40]. These results suggest that any 
one of the three ILTV glycoproteins (gB, gC and gD) may be useful as a subunit ILTV 
vaccine individually or in combination. 
2.2 ILTV pathogenicity and immunity 
ILTV has  a  very  narrow  host  range,  not  only  in‐vitro,  but  also  in‐vivo.  
ILTV  can  be propagated  in  embryonated  chicken  eggs  and  in  primary  kidney  and  
liver  cell  cultures  of chicken  or  chicken  embryos  [41,  42].  ILTV primarily infects 
chickens but can also infect pheasants and peafowl [1, 43]. Natural infection of turkeys is 
rare [44], unless experimentally infected [45].  ILTV infection predominantly affects the 
mucosa and submucosa of the upper respiratory tract, but conjunctivitis is also frequently 
observed. Depending on virus dose and strain, the incubation period can vary from 2 to 
12 days. Like other herpesviruses, ILTV can establish felong latent infection in the 
central nervous system [46, 47], where the ILTV genome could be detected 
predominantly within the trigeminal ganglion [48]. 
ILTV infection induces the production of IgG, IgM and IgA antibodies directed 
against ILTV proteins. Virus neutralizing antibodies in the serum are first detected within 
5‐7 days after infection and can remain for a year or m e [49]. Mucosal antibodies (IgG 
and IgA) are detected in tracheal secretion from approximately 7 days after infection [49, 
50]. CMI has not been studied directly because of the complexity of requirements in 
conducting CMI experiments in chickens, but is thought to play an important role in 





2.3 ILTV vaccine development 
Vaccination with live‐attenuated vaccines has been the principal method for 
prevention and control of ILT [1]. Current live attenuated ILTV vaccines are prepared 
either by serial passage in chicken embryo or by serial passage in tissue culture. These 
vaccines confer long lasting protection against pathogenic ILTV strains [1].  However,  
these  vaccines  are empirically made and many  of  them  possess residual  virulence,  
which  can further  increase during animal passage [52, 53]. It is believed that most ILT 
outbreaks in the USA are caused by vaccine‐related isolates that persist in the field [54].  
Furthermore, ILT vaccine virus may become latent and reactivation of which can lead to 
ILT outbreak [3]. 
  Several strategies have been attempted for the dev lopment of a vaccine that has 
reduced potential for clinical disease and latency. One of the strategies has been creation 
of ILTV mutants for use as live‐virus vaccines. Although attempts have been made to 
engineer stable  attenuated  ILTV  mutants,  these  att mpts  have  not  been  successful  
due  to  lack  of infectious full length clones of ILTV genome and  availability  of 
suitable cell lines for in‐vitro replication and manipulations. Nevertheless, ILTV 
recombinants with deletion of at least 14 different genes have been generated by 
cotransfection of chicken cells with viral DNA and transfer plasmids [7].  A  thymidine  
kinase  (TK)  gene‐deleted  ILTV  expressing  the  green fluorescent  protein  gene  was  
shown  to  be  nonpathogenic,  but  showed  protecti n  against virulent virus challenge 
similar to commercial vaccine [55]. One of the disav ntages of using recombinant ILTV 




that the gene‐deleted vaccine virus  could become virulent after recombination with 
wild‐type virus, as has been demonstrated for Prv vaccine [56, 57]. 
 Live  virus‐vectored  vaccines  for  immunization  of  chickens  against  ILTV  
have  been developed [22, 58]. A recombinant herpesvirus of turkey (HVT) containing 
ILTV gene produced protection against virulent ILTV challenge similar to that induced 
by a commercial vaccine (CEO) [59]. This vaccine is commercially available and may be 
administered to one‐day old chickens subcutaneously or in‐ovo to 18‐day old chicken 
embryos.  A  recombinant  fowl  pox  virus containing  ILTV‐gB  gene  also  produced  
protection  against  virulent  ILTV  challenge  [22,  58]. 
  Another fowl pox virus recombinant containing ILTV‐ gB and UL‐32 gene has 
been constructed and  this  virus   also  provided  adequate  immunity  against  virulent  
ILTV  challenge  [60].  A recombinant fowl pox vaccine with ILTV genes is 
commercially available in the United States. This vaccine is recommended for use via 
wing‐web administration in healthy one‐week old chicks or in‐ovo in 18‐day old chicken 
embryos. 
        All studies conducted to date suggest that a virus‐vectored ILTV vaccine will be 
most effective for prevention and control of ILT. A vectored‐vaccine will be safe and not 
lead to reversion to virulence or establishment of latency. Several viruses such as 
fowlpox, adenovirus, adeno‐associated virus, NDV and HVT are available for usea  
vaccine vectors. But each viral vector has its own advantages and disadvantages for use 
as a vaccine vector for ILTV. Some of the desirable properties for an ILTV vaccine 
vector are: i) the vector must have a proven track record  of  safety;  ii)  ability  to  




respiratory tract; iv) expression of the ILTV antigen in proper conformation; and  v)  
expression  of  the  ILTV  antigen  in  a  quantity  sufficient  for  induction  of  a  strong 
neutralizing antibody and CMI responses. 
 There are  several  features  that  make  rNDV  an  attractive  vector  for  ILTV  
vaccine. Avirulent NDV strains have been widely used as vaccines for more than 50 
years with a proven record of safety and efficacy.  NDV is a respiratory pathogen and 
efficiently induces mucosal immunity at the respirato y tract, which is also the site of 
replication for ILTV. NDV induces strong systemic IgG antibody and CMI responses 
[15]. NDV replicates in the cytoplasm and does not integrate into the host genome 
obviating concerns about cellular transformation.  In the United States, NDV vaccines are 
applied by course‐spraying of day‐old chicks. Therefore, an NDV vectored ILTV vaccine 
can be applied to a large number of one‐day old birds in a short time. 
2.4 Newcastle disease virus (NDV) 
NDV  causes  serious  respiratory  and  neurological  disease  in  all  species  of  
birds. Newcastle disease varies in degree of severity, ranging from an inapparent 
infection to severe disease causing 100% mortality. NDV strains are categorized into 
three main pathotypes, depending upon the severity of he disease produced in chickens 
[61].  Lentogenic strains do not cause disease and are considered avirulent. Viruses of 
intermediate virulence are termed “mesogenic”, while virulent viruses that cause high 
mortality are termed “velogenic”.  Several lentogenic and mesogenic strains of NDV are 
currently used as live attenuated vaccines in chickens [62].      
NDV is a member of the genus Avulavirus of the family Paramyxoviridae [63].   




nucleotides [64, 65] (Fig.2.).  The genomic RNA contai s six genes, which encode at 
least seven proteins [65, 66]. Three proteins constitute the nucleocapsid‐ the 
nucleocapsidprotein (N), the phosphoprotein (P), and the large polymerase protein (L).   
Two proteins form the external envelope spikes, namely, the F and HN proteins.  The 
matrix protein (M) forms the inner layer of the virion.  The genomic  RNA  is  tightly 
bound  by  the  N  protein  and  with  the  P and  L  proteins  form  the functional 
nucleocapsid within which reside the viral transcriptive and replicative activities.  In 
common with several other paramyxoviruses, NDV produces a seventh protein (V) by 
editing of the P gene [65, 67]. 
NDV  follows  the  general  scheme  of  transcription  and  replication  of  other  
non‐ segmented  negative‐strand  RNA  viruses  [68]. The  polymerase  enters  the  
genome  at  a promoter  in  the  3’  extragenic  leader  region  and  proceeds  along  the  
entire  length  by  a sequential stop‐start mechanism during which the polymerase 
remains template‐bound and is guided  by  short  conserved  gene‐start  (10  nt)  and  
gene‐end  (10  nt)  signals  (Fig.2).  This generates a free leader RNA and six 
non‐overlapping subgenomic mRNAs.  However, 20‐30% of  the  polymerase  fails  to  
reinitiate  transcription  of  the  downstream  genes. Thus, the abundance of the various 
mRNAs decreases as the distance from the promoter increases.  The genes are separated 
by short intergenic regions (1‐47 nucleotides), which are not copied into the individual 
mRNAs.  The 3’ terminus (leader) and the 5’ terminus (trailer) of the genomic RNA 
contain cis‐acting sequences important for replication, transcription, and packaging of 
viral RNA [68].  RNA replication occurs when the polymerase switches to a read through 








Fig. 2. Genomic map of NDV. 
 
2.5 Generation of recombinant NDV from plasmid DNA 
The genomic or antigenomic RNA of negative‐stranded RNA viruses is not 
infectious alone.  Other components of the ribonucleoprotein (RNP) complex, namely, N. 
P and L proteins, are essential to transcribe the genomic RNA into mRNAs resulting in 
viral protein production and initiation of infection. Therefore, the current technique of 
genetic manipulation of negative‐strand RNA viruses by reverse genetics involves 
co‐transfection into permissive cells with plasmids expr ssing full‐length RNA and N, P 
and L proteins, all under the control of the T7 promoter.  This results in reconstitution of 
the RNP complex inside the cell and recovery of the inf ctious virus. The source of T7 
RNA polymerase is either a recombinant vaccinia virus expressing the T7 RNA 
polymerase [69, 70], or a cell line constitutively xpressing the T7 RNA polymerase [71]. 




virus to be recovered entirely from cDNA [72].  Since then, several non‐segmented, 
negative‐strand RNA viruses have been recovered from cloned cDNAs [73‐77]. 
  
We  have  applied  these  principles  to  recover  lentogenic  NDV  strain  LaSota  
[10], mesogenic NDV strain Beaudette C [64] and velog nic NDV strain Texas GB [78] 
from cloned cDNAs. The NDV‐derived cDNA sequence was assembled from RT‐PCR 
products obtained using specific primers and viral RNA of the NDV strain.  This cDNA 
(15,186nt) was flanked by a T7 promoter and by the hepatitis delta virus ribozyme 




Fig. 3. Assemblies of full‐length antigenome of NDV strain LaSota in pBR322. RT‐PCR 
fragments of NDV antigenome was assembled between th  T7 promoter and hepatitis 
delta virus ribozyme as shown in a sequential manner. During construction of the 
full ‐length NDV cDNAs, several genetic markers were introduced into the intergenic 




2.6 Generation of rNDV expressing foreign genes 
 The modular organization of NDV genome makes it easy to insert foreign genes.  
The introduction of a foreign gene flanked by viral tr nscription gene‐start and gene‐ nd 
signals results in transcription of an additional mRNA (Fig. 4). 
 
 
Fig. 4. Schematic diagram of insertion of a foreign gene into NDV antigenome. Empty 
boxes represent insertion sites used in our laboratory. 
 
We also include an optimal Kozak translation sequence just upstream of the ATG.  
For optimal replication, the final NDV genome length is adjusted so that it is divisible by 
six [79], a requirement known as the “rule of six” that is common to most 
paramyxoviruses. 
We  have  been  successful  in  expressing  several  vi l  and  bacterial  proteins  
using recombinant NDV as a vector [11‐ 8]. We have also recovered rNDVs expressing 
two foreign genes. In all cases, it was demonstrated that the rNDV expressed the foreign 
protein to high levels, and the expression of foreign proteins was stable for many 
passages (at least 10). Although the upper limit for insertion of a foreign gene in NDV 
vector is not known, we have been able to insert the S gene of SARS‐CoV (3·9kb) into 
the rNDV genome [16]. The rNDV‐ SARS/S was recovered without much difficulty and 




Chapter 3: Materials and Methods 
 
3.1 Cells and Viruses  
Human epidermoid carcinoma (HEp-2), chicken embryo fibroblast (DF1), and Vero 
cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, 
VA). HEp-2, DF1, and vero cells were grown in Dulbecco's modified Eagle medium 
(DMEM) containing 10% fetal bovine serum (FBS) and maintained in DMEM with 5% 
FBS. Chicken embryo liver cells (CELi) were harvested from 11 -12 day old specific 
pathogen free embryonated chicken eggs by conventional trypsin disaggregation method 
and were grown in Eagle’s minimal essential medium (EMEM) containing 10% FBS. 
The chicken‐embryo‐origin ILTV vaccine Trachivax was obtained from the Schering‐ 
Plough Animal Health Corp, Millsboro, DE. The USDA challenge strain of ILTV was 
obtained from the National Veterinary Services Labor tory, Ames, IA, USA. The USDA 
ILTV challenge strain was propagated on monolayers of chicken embryo liver cells. 
Recombinant NDV strains were grown in 9-day-old specific-pathogen-free (SPF) 
embryonated chicken eggs. The modified vaccinia virus Ankara strain expressing T7 
RNA polymerase was grown in primary chicken embryo fibroblast cells. 
3.2 Isolation of ILTV DNA 
The chicken‐embryo‐origin ILTV vaccine Trachivax (Schering‐ Plough Animal 
Health Corp, Millsboro, DE) was used as the source for ILTV DNA. Briefly, ILTV was 
propagated in chick embryo liver (CELi) cells. Virus cultures was harvested when 
moderate level of cytopathic effects (CPE) characteized by rounding and syncytia 




thaw cycles. Cellular debris was  removed  by  slow  centrifugation  at  1000Xg  for  10  
min  at  4OC. Virus  was   harvested  by pelleting he clarified supernatant through 30% 
sucrose cushion in phosphate‐buffered saline at 100,000 g for 60 min. The virus pellet 
was suspended in 0.05 M Tris–HCl, 0.15 M NaCl, 10 mM  EDTA  (pH  8.0)  and  
applied  to  a  20  to  50%  potassium‐sodium  tartrate  discontinuous gradient and 
centrifuged at 100,000 g for 90 min. After centrifugation, the virus band was collected,  
diluted  in  PBS,  and  pelleted  at  75,000  g  for 60  min.  Viral DNA was purified 
according to the method of Summers et al. [82]. Briefly,  purified virus was suspended in 
extraction buffer (0.1M Tris–HCl, 0.15M NaCl, 0.1 M EDTA, 0.1 M KCl, pH 7.5) 
containing 45 µg of  proteinase  K  per  ml  and  icubated  at  50˚C  for  1  h.  Sarkosyl 
was added to a final concentration of 1%, and the sample was incubated at 50˚C for an 
additional 1 h. The sample was extracted twice with phenol‐chloroform‐isoamyl alcohol 
(25:24:1) and precipitated with ethanol. The DNA pellet was resuspended in 0.05 M 
Tris–HCl, 10 mM EDTA, pH 8.0. 
3.3 Modification of ILTV gB gene 
 ILTV gB gene is 2652 nucleotides in length and hasa guanine plus cytosine ratio of 
44.53%. Detailed scanning of ILTVB gB gene demonstrated sequence similarities to 
NDV strain LaSota gene end signals at nucleotide positions(ORF positions)  566-573 and 
889-894 which contains poly A tail consisting of more than six repeated adenine bases. 
These signals could be potentially read as gene ends by viral RNA polymerase leading to 
premature termination of transcription. Therefore, we have modified the gB gene at 
above said nucleotide positions by overlapping PCR methodology and without altering 




modified nucleotides and their positions is shown in the following table (Table.1). 
Modified gB was used for subsequent cloning into rNDV vector. 
 
 
Mutagenesis at 567,570 and 573 ORF positions of ILTV gB gene 
          5’-AAT GAT GAA GCA GAa AAa AAa TTG CCC CT G GTT CCA TCA CTG-3' 
5'-AAT GAT GAA  GCA Ga g  AAg AAg TTG CCC CTG GTT CCA TCA CTG-3' 
(Nucleotides at positions 567,570 and 573 in wild type gB (first row) are shown in lower case 
and their modifications are shown in modified gB (second row) in lower case red). 
 
 
Mutagenesis at 891 and 894 ORF positions of ILTV gB gene 
   5'-ATA AGA CCC CCT AAa AAa AGA AAC TTT CTA ACA GAT GAA  -3' 
   5'-ATA AGA CCC CCT AA g AAg AGA AAC TTT CTA ACA GAT GAA -3 ' 
(Nucleotides at positions 891 and 894 in wild type gB (first row) are shown in lower case and 
their modifications are shown in modified gB (second row) in lower case red). 
 
 
Table 1. Modification of ILTV gB gene 
 
3.4 Cloning of ILTV gB, gC and gD genes 
Three sets of PCR primers were used to amplify the ORF of gB, gC and gD genes of 
ILTV. Sequences of three primer sets are gB (forward), 
5’GATCGTTTAAACTTAGAAAAAATACGGGTAGAAGGCCACCatgcaatcctacatcgcg 







tttatttttgag3’;gD(reverse)5’GGCCGTTTAAACttagctacgcgcgcattttacg   3’.   All   primers   
contains   PmeI   sites (italicized),  the  NDV  gene  end  and  gene  start  transcriptional  
signals  (underlined),  the  T intergenic nucleotide (boldface), additional nucleotide in 
order to maintain the genome length as a multiple of six (italicized and bold), and a  
six‐nucleotide Kozak sequence for efficient translation  (bold,  underlined).  The 
ILTV ‐specific sequence is in   small case.  PCR was performed using 100 ng of 
pre‐denatured viral DNA, 50 pmol of each primer, 2 × GC  buffer I containing Mg2+, 
200 µM dNTPs, 0.5 units of TaKaRa LA Taq™ polymerase (Takar  Bio USA, Madison, 
WI). PCR will be carried out for 30 cycles under the following conditions; 1 min at 94OC 
for denaturation of the template, 1 min at 55OC for primer annealing and 3 min at 72OC 
for chain extension.  After  amplification,  the  2652,  1245  and  1134  base  pair  
products  were digested with PmeI and cloned into pCR 2.1‐TOPO vector (Invitrogen). 
The integrity of the gB, gC and gD genes was confirmed by sequence analysis. 
3.5 Construction of rNDV cDNAs containing gB, gC and gD genes of ILTV 
In the present study, we have inserted additional transcriptional units containing 
ILTV gB, gC and gD genes between the P and M genes of NDV. Based on previous 
studies from our laboratory, large size inserts can be placed between the P and M genes 
without affecting virus replication [11]. The NDV plasmid used in this study is a 
full ‐length cDNA of the antigenomic RNA of NDV strain LaSota that was modified to 




The TOPO  vectors  bearing  the  glycoproteins  (gB,  C  and  gD)  gene  of  ILTV  
were  digested with PmeI and cloned at the unique Pm I site between P and M genes of 
full ‐length NDV plasmid to yield pNDV‐gB, pNDV‐gC and pNDV‐gD (Fig. 5). The 
resulting plasmids were sequenced to confirm orientation and the absence of adventitious 
mutations. 
 
   
 
Fig. 5 Construction of NDV cDNAs containing ILTV gen s 
 
3.6 Antisera production in rabbits 
The anti- ILTV antiserum was raised in rabbits against the synthetic peptides of gB, 
gC, and gD proteins of ILTV. Synthetic peptides of ILTV gB, gC and gD proteins were 
obtained from GenScript USA Inc., Piscataway, NJ, USA. Briefly, rabbits were injected 




at 14 day interval time. Synthetic peptides were homogenized with the Freund’s complete 
adjuvant in equal proportion for the initial dose, but for the booster doses mixture of 
synthetic peptides and Freund’s incomplete adjuvant in equal proportion was used.  The 
rabbits were bled after the final booster and the serum samples were collected. The 
specificity of the antiserum was determined by Western blot analysis. 
3.7 Transfection 
The recombinant viruses were recovered using the rev rs  genetics techniques as 
depicted in Fig. 6. Briefly, HEp‐2 cells were used for transfection experiments because 
these cells are permissive for NDV, transfect efficiently, and are resistant to CPE of 
vaccinia virus strain MVA expressing the T7 RNA polymerase.  A mixture of three 
plasmids containing NDV N, P and L (0·4µg, 0·3µg, and 0·2µg per well, respectively) 
and a fourth plasmid encoding the full‐ length  NDV  antigenome  carrying  the  ILTV  
sequences  (4.0µg)  were  transfected   with Lipofectamine (Invitrogen) and infected with 
MVA.  Four hours after transfection, the cells were washed twice and replaced with 
medium containing acetyl‐trypsin (1µg/ml). Forty‐eight hours after transfection, the cells 
were scraped, sonicated and centrifuged at 1000 xg for 5 min. The clarified supernatant 
was used to infect HEp‐2 cells. After two passages in HEp‐2 cells, 100µl clarified 
supernatant was used to inoculate into the allantoic cavity of 10‐day‐old embryonated 
chicken eggs. The allantoic fluid was harvested 4 days later and tested for HA. 
3.8 Reverse transcription PCR (RT-PCR) and sequence analysis of cloned ILTV 
genes 
Total RNAs were isolated from the rNDVs infected allantoic fluid in the 9-day-




manufacturer’s recommendations. Reverse transcription was performed using 
SuperScript II reverse transcriptase (Invitrogen). The positive-sense primer used for RT 
reaction was NDV P gene 3120(P3120F) Forward primer, 5' 
CGGAATCTGCACCGAGTT 3' for all rNDV’s carrying ILTV genes.  For rNDV-gB, 
the generated cDNA product was PCR amplified using primers, P3120F and gB 500R 5' 
CATTCTCCCGATCGATCAAT 3'. For rNDV-gC, the primers, P3120F (+) and gC 
500R (-) 5' GTTGTAGGTGGTCTTGCCAA 3', were used for the PCR amplification. 
For rNDV-gD, the primers, P3120F (+) and gD 500R (-) 5' 
AGCAAGTATTGGCCAGAGAG 3', were used for the PCR amplification. The RT-PCR 





Fig. 6. Method of transfection and rescue of recombinant NDV‐ILTV (The figure was 





3.8 Western blot analysis  
The expression of gB, gC and gD proteins by rNDVs was examined by Western blot 
analysis. Briefly, DF1 cells were infected with rNDV’s at an MOI of 0.1 and were 
harvested at 48 h post- infection. Further, DF-1 cells were lysed using RIPA-PMSF 
buffer and analyzed by Western blot using peptide antisera against gB, gC and gD 
proteins. To examine the incorporation of ILTV glycoproteins into NDV particles, 
Western blot analysis was carried out using purified virus and peptide antisera against 
gB, gC and gD proteins. 
3.9 Growth kinetics of rNDV’s expressing ILTV gB, gC and gD 
The growth kinetics of rNDV’s expressing ILTV gB, gC and gD were determined by 
multicycle growth curves in DF1 cells. Briefly, DF1 cells were infected with viruses at a 
MOI of 0.01 PFU and the cell culture supernatant samples were collected at 12-hour 
intervals until 60 hours post-infection. The titers of virus in the samples were quantified 
by plaque assay in DF1 cells. All plaque assays were performed in 12-well plates. 
Briefly, supernatants collected from the virus infected DF-1 cell samples were serially 
diluted and each dilution (200 µL) was infected to 12 well plate DF-1 cells in duplicates. 
After 1 h adsorption, cells were covered with DMEM containing 2% FBS, 0.8% 
methylcellulose, and incubated at 370C in 5% CO2. Four days later, the cells were fixed 
with methanol and stained with crystal violet for enumeration of plaques. 
3.10 Mean death time of rNDV’s expressing ILTV gB, gC and gD 
Mean death time was determined by inoculating the diluted virus (10-6 to 10-9) into 
9-days-old embryonated eggs (5 eggs for each diluent).  The viability of embryo in the 




recorded and the highest dilution at which all five embryos died was considered as the 
minimum lethal dose. The MDT was calculated as the mean time in hours taken by the 
minimum lethal dose to cause the death of all the embryos. 
3.11 Immunofluorescence assay    
The expression of ILTV proteins by the recombinant viruses was examined in vero 
cells by immunofluorescence assay. Briefly, confluent monolayers of vero cells on 4 well 
Lab-Tek chamber slides were infected with the recombinant viruses at a multiplicity of 
infection (MOI) of 0.1. After 24 h, the infected or control cells were washed with 
phosphate buffered saline (PBS) and either fixed with 4% paraformaldehyde for 20 min 
at room temperature for detection of surface antige, or fixed with 4% paraformaldehyde 
for 20 min at room temperature and permeabilized with 0.2% Triton X-100 in PBS for 10 
min for detection of total antigen. After further washing with PBS, the cells were 
incubated for 30 min with 3% normal goat serum to block nonspecific binding sites and 
incubated for 1 h with 1:50 dilution of respective rabbit polyclonal anti-ILTV antiserum. 
The cells were rinsed with PBS and incubated with 1:1000 dilution of Alexa Fluor 488 
conjugated goat anti-rabbit immunoglobulin G antibody (Invitrogen, Carlsbad, CA) for 
45 min. The cells were washed with PBS and analyzed with a fluorescent microscope. 
3.12 Evaluation of the genetic stability of rNDV’s containing ILTV glycoprotein 
genes 
The genetic stability of rNDV’s containing ILTV glycoprotein genes was evaluated 
by 10 serial passages in 9- day old SPF eggs and 10 serial passages in DF-1 cells. Virus 




DF-1 cell supernatant and subjected to sequence analysis to determine the genetic 
integrity of the cloned ILTV genes. 
3.13 Immunization and Challenge experiments in chickens 
The immunogenicity and protective efficacy of the rcombinant viruses against 
virulent ILTV were evaluated in specific pathogen free (SPF) chickens obtained from 
Charles River Laboratories, Wilmington, MA, USA. All of the animals used in this study 
were housed in isolator cages in our biosafety level 2+ facility and were cared for in 
accordance with established guidelines, and the exprimental protocols were performed 
with the approval of Institutional Animal Care and Use Committee (IACUC) of the 
University of Maryland and under Animal Welfare Association (AWA) regulations. The 
challenge experiment with virulent NDV strain Texas-GB was carried out in an enhanced 
BSL3 containment facility certified by the USDA and CDC, with the investigators 
wearing appropriate protective equipment and compliant with all protocols approved by 
the Institutional Animal Care and Use Committee (IACUC) of the University of 
Maryland and under Animal Welfare Association (AWA) regulations. 
Immunization experiment 
Two‐week‐old SPF white leghorn chickens were assigned to 10 groups of 26 chickens 
each and placed in isolation units maintained under egative pressure (Table.4). A group 
1 was remaining unvaccinated and serves later as chllenge controls. Group 2 was 
vaccinated with recombinant NDV strain LaSota vaccine by oculonasal instillation of 106 
EID50 of virus.  Group 3 was vaccinated with the CEO vaccine Trachivax   
(Schering‐Plough   Animal   Health   Corp,   Millsboro,   DE)   as   per   manufacturer’s 




Group No Chickens Vaccine virus Challenge virus 
1 26 Challenge control (13 birds) NDV‐GB Texas. 
(13 birds) USDA ILTV . 
2 26  rNDV LaSota vaccine (13 birds) NDV‐GB Texas. 
(13 birds) USDA ILTV.  
3 26 Trachivax (13 birds) NDV‐GB Texas. 
(13 birds) USDA ILTV. 
4 26 rNDV‐gB (13 birds) NDV‐GB Texas. 
(13 birds) USDA ILTV. 
5 26 rNDV‐gC (13 birds) NDV‐GB Texas. 
(13 birds) USDA ILTV. 
6 26 rNDV‐gD (13 birds) NDV‐GB Texas. 
(13 birds) USDA ILTV. 
7 26 rNDV‐gB + rNDV-gC (13 birds) NDV‐GB Texas. 
(13 birds) USDA ILTV. 
8 26 rNDV‐gB + rNDV-gD (13 birds) NDV‐GB Texas. 
(13 birds) USDA ILTV. 
9 26 rNDV‐gC + rNDV-gD (13 birds) NDV‐GB Texas. 
(13 birds) USDA ILTV. 
10 26 rNDV-gB + rNDV-gC + 
rNDV-gD 
(13 birds) NDV‐GB Texas. 
(13 birds) USDA ILTV. 
 
Table.4. Protocol for evaluating the immunogenicity of rNDVs expressing envelope 






Groups 4, 5 and 6 were received 106 EID50 of each rNDVs  expressing ILTV gB, ILTV 
gC and ILTV gD respectively by oculonasal instillaton. Group 7 received a mixture of 
106 EID50 each of rNDV-gB and rNDV-gC, group 8 received a mixture of 106 EID50 
each of rNDV-gB and rNDV-gD, group 9 received a mixture of 106 EID50 each of 
rNDV-gC and rNDV-gD, and group 10 received a mixture of 106 EID50 each of rNDV-
gB, rNDV-gC and rNDV-gD by oculonasal instillation respectively. The chickens were 
immunized with a single dose of rNDV’s in a total volume of 0.2 ml (0.05 ml in each eye 
and nostril). Three weeks post-immunization, prechallenge serum samples were collected 
for serum antibody response, and chickens in each group were divided into two 
subgroups of 13 chickens  each,  one  subgroup  wastr nsferred  to  enhanced BSL3  
facility  for  NDV  challenge.  The remaining chickens were kept in BSL‐2+ facility for 
virulent ILTV challenge. 
Challenge experiment 
NDV Challenge 
Each bird in all groups (n=13) were challenged by ocul nasal route with 104.5 
ELD50 of Velogenic NDV strain Texas GB. Birds were observed daily for 2 weeks for 
clinical signs (death, paralysis, and torticollis) of neurotropic NDV. In order to determine 
the replication of challenge virus, three chickens from each group were sacrificed on day 
3 post challenge. Tissue sample (trachea, lungs, and brain) were collected, homogenized 
in cell culture medium DMEM containing antibiotics (1gm/10ml) and clarified by 







Each bird in all groups (n=13) were challenged after 3 weeks of vaccination with 
0.2 ml of a USDA ILT challenge virus (NVSL, Ames, IA) intratracheally (106  
TCID50/bird). All birds were observed daily for 14 days post challenge for clinical signs 
of respiratory disease, conjunctivitis and mortality. A daily total clinical sign score was 
calculated for each group following the scoring system described by Oldoni et al [54].  
In order to determine the replication of challenge virus, three  chickens  from  
each  group  were  sacrificed  on  day  4  post  challenge.  The tracheal tissue was 
observed for macroscopic lesions and then collected in cell culture medium DMEM 
(1g/mL) containing antibiotics and homogenized. The challenge virus titers in the 
homogenates were determined by TCID50 method in chicken embryo liver cells using 
Reed and Muench method as described previously (86). 
  The remaining ten chickens in each group were observed daily for 14 days for 
disease signs and mortality following challenge. Post challenge serum was collected from 
the surviving birds before they were sacrificed on day 14 post challenge. For detection of 
latent infection, trigeminal ganglia were removed from all the surviving birds on day 14 
post challenge as described by Williams et al [47]. The trigeminal ganglia were 
homogenized in cell culture medium DMEM containing antibiotics, centrifuged and the 
supernatant was used for the extraction of ILTV DNA [48]. The DNA was isolated using 
Qiagen’s QIAamp DNA mini kit (250) according to manufacturer protocols. The 
amplification of the TK gene of ILTV DNA was conducted by nested PCR using primer 
pairs from published TK gene sequence [84]. The prime s used were shown in the 




TK-I Forward: 5'-ACTTCCGGTGGTGTGCAGTTTTGC-3' 
TK-I Reverse: 5'-TATCAGCATTGTAGCGCT-3' 
TK-II Forward: 5'- AGGCTTCCGGAAAACTTGAATGTC-3' 
TK-II Reverse: 5'- TCTTGAATTTTAAGAGCG-3' 
 
Table.5. Primers used in Nested PCR for amplification of TK gene from ILTV DNA 
collected from trigeminal ganglion. 
 
3.14 Scoring of clinical signs 
All the birds challenged with USDA strain of ILTV were observed daily for 14 days 
post challenge for clinical signs of respiratory disease, conjunctivitis and mortality. 
Clinical signs were scored according to the scoring system described by Oldoni et al [54]. 
The following procedure is extracted from the Oldoni et al (54). Clinical signs were 
scored on the basis of breathing patterns, conjunctivitis, the level of depression, and 
mortality observed per unit per day. A daily total clinical sign score was calculated for 
each unit. Dyspnea was scored on a scale of 0 (normal breathing), 1 (mild dyspnea and 
open mouth breathing) and 2 (gasping with an extended neck). The condition of the 
conjunctiva was scored on a scale of 0 (normal), 1 (swollen and/or partial closure of the 
eyes) and 2 (complete closure of the eyes). The level of depression was scored on a scale 
of 0 (normal, or not depressed), 1 (depressed) and 2 (severely depressed). For mortality, 
the score was 0 (no mortality) and 3 (mortality). Statistical analysis was performed to 




Multiple comparisons with baseline values were made using a Bonferroni correction to 
limit the overall type-I error rate to 5%. 
3.15 Serological analysis 
The antibody levels of serum samples collected from chickens vaccinated with 
rNDV’s were evaluated by hemagglutination inhibition (HI), virus neutralization (VNT) 
assay, and enzyme-linked immunosorbent assay  usingsta dard protocols (86). 
NDV specific antibody response in the serum samples collected from the birds was 
measured by hemagglutination inhibition (HI) assay. For the HI assay, twofold serial 
dilutions of immunized chicken sera (50 µL) were prepared, and each dilution was 
combined with 4 HA units of rNDV. Following 1 h of incubation, 50 µL of 1% chicken 
RBC was added and incubated for 30 min at room temperature, and hemagglutination 
was scored. 
ILTV specific antibody response in the serum samples collected from birds was 
measured by enzyme-linked immunosorbent assay (ELISA) and virus neutralization 
(VNT) assays. Serum samples were analyzed by ELISA using the LTELISA kit 
(ProFLOCK® LT ELISA Kit, Synbiotics Corp., San Diego, CA) following the 
manufacturer’s instructions. ILTV neutralizing antibody titers were also determined by 
virus neutralization assay performed in 96-well plates with chicken embryo liver cells. 
Briefly, each serum sample was heated at 560c for 30 minutes to destroy heat-sensitive, 
non-specific virus inhibitory substances. Six two-fold dilutions in duplicate were 
performed for each serum in minimum essential medium containing proper antibiotics. 
Each dilution was mixed with 100 TCID50 of USDA ILTV virus in 96-well plate and 




and adsorbed into chicken embryo liver cell monolayers. The plate was incubated for 5 
days at 370c.  After 5 days of incubation, the plate was examined for the presence of 
ILTV cytopathic effect and the VN titer was estimated as the reciprocal of the first serum 
dilution were ILTV cytopathic effect was observed. 
3.16 Statistical analysis 
Statistically significant differences in data from serological analysis of different 
immunized chicken groups were evaluated by one-way analysis of variance (ANOVA) 
with the use of Prism 5.0 (Graph Pad Software Inc., San Diego, CA) at a significance 


















Chapter 4: Results 
 
4.1 Construction of rNDV cDNAs containing gB, gC and gD genes of ILTV 
The recombinant lentogenic NDV strain LaSota containing a unique PmeI site 
between the P and M genes was used as a vector to express the ILTV glycoprotein from 
an added gene. The ILTV gB, gC and gD genes were amplified by PCR from genomic 
DNA extracted from purified ILTV virions. ILTV gB gene appeared to possess sequence 
similarities to NDV strain LaSota gene end signals t nucleotide positions(ORF 
positions)  566-573 and 889-894 which contains poly A tail consisting of more than six 
repeated adenine bases. These signals could potentially leads to the premature 
termination of transcription by viral RNA polymerase. Therefore, we have modified the 
gB gene at above said nucleotide positions by overlapping PCR and the modified gB was 
used for subsequent cloning into rNDV vector. The gB, C and gD ORF’s were placed 
under the control of NDV transcriptional signals and i serted at the PmeI site between the 
P and M genes in the NDV vector. The transcription cassette was designed to maintain 
the rule of six, whereby the genome nucleotide length must be an even multiple of six in 
order to be efficiently replicated. A Kozak sequenc was inserted before the start codon 
of the gB, gC and gD gene ORF to provide for efficient translation. The resulting 
plasmids were designated as pNDV-gB, pNDV-gC and pNDV-gD and their sequencing 
analysis indicated absence of any adventitious mutations and also confirmed that ILTV 





4.2 Recovery and characterization of recombinant NDVs containing gB, gC and gD 
genes of ILTV 
4.2.1 Antisera production in rabbits 
Anti-ILTV antibodies in the rabbit serum were titrated using ILTV-ELISA kit 
from Synbiotics Corporation, San Diego, California, USA. The sequences of the 
synthetic peptides used and their respective anti-ILTV antibody titers are shown in the 
following table (Table 2). 
Peptide Sequence Anti-ILTV antibody titer 





















Anti-ILTV gD : 5987 
Table 2.  Synthetic peptides used for the production of rabbit polyclonal antisera and their 




4.2.2 Recovery of rNDVs containing the glycoprotein genes of ILTV and their 
evaluation of genomic integrity 
The recombinant viruses, designated as rNDV-gB, rNDV-gC and rNDV-gD were 
recovered using the reverse genetics method available in our laboratory. The structure of 
gB, gC and gD inserts in the genome of these viruses was confirmed by RT-PCR (Figure 
7) and nucleotide sequence analysis. All the recombinant viruses were propagated in 
embryonated chicken eggs and the titers were determin d by HA assay. The HA titers of 
recombinant viruses were 1–2 log2 lower than that of the parental rLasota virus. This 
result is consistent with previous findings that a moderate attenuation of replication can 
result from the insertion of a foreign gene (64). To determine the stability of the ILTV 
genes in the recombinant viruses, the recovered viruses were passaged ten times in 
embryonated chicken eggs and ten times in chicken embryo fibroblast DF-1 cells. 
Sequence analysis of the ILTV genes of the resulting v rus preparations showed that the 
integrity of the ILTV genes was preserved and stably maintained even after 10 passages. 
 
Figure 7. RT-PCR analysis of the ILTV genes from recombinant NDVs. Lane 1: 
Invitrogen 1 Kb+ ladder, Lane 2: RT-PCR product amplified from genomic RNA isolated 
from rNDV-gB infected allantoic fluid, Lane 3: RT-PCR product amplified from 
genomic RNA isolated from rNDV-gC infected allantoic fluid and, Lane 4: RT-PCR 







Figure 7. RT-PCR analysis of the ILTV genes from recombinant NDVs. 
 
4.2.3 Expression of ILTV glycoproteins by recombinant viruses 
The expression of ILTV glycoproteins in DF-1 cells infected with recombinant 
viruses was analyzed by western blot using rabbit ant -ILTV peptide antisera (Figure 8). 
Immunoblot analysis detected two bands in lysates of cells infected with rNDV-gB: these 
represented (i) dimer form of gB with an apparent molecular weight of 100 kDa and (ii) 
mature processed form of gB with an apparent molecular weight of 58kDa. Immunoblot 
analysis detected 60kDa and 42kDa bands in rNDV-gC and rNDV-gD infected DF-1 cell 
lysates respectively. Surprisingly, only the ILTV glycoprotein C (gC) was found to be 
incorporated into the envelope of recombinant virus. ILTV glycoprotein B and D were 




We also used immunofluorescence to determine the intracellular and surface 
expression of the ILTV glycoproteins in vero cells infected with recombinant viruses. 
Positive staining was observed for cells infected with rNDV-gB and rNDV-gD using 
rabbit anti-ILTV antiserum (Figure 9. Immunofluoresc nce analysis of vero cells infected 
with rNDV, rNDV-gB and rNDV-gD for intracellular expression and surface expression 
of ILTV proteins. Vero cells were infected with rNDV (panel B, D, F, and H), rNDV-gB 
(panel A and C) and rNDV-gD (panel E and G) and probed with rabbit anti-ILTV gB 
antibodies (panel A, B, C, and D) and rabbit anti-ILTV gD antibodies (panel E, F, G, and 
H) for intracellular antigen ( panel A, B, E, and F) as well as surface expression (panel C, 
D, G, and H) of ILTV proteins.). We were not able to show the internal and surface 
expression of ILTV proteins for cells infected with rNDV-gC, although, the rabbit 
antisera detected ILTV gC protein in DF-1 cells infected with rNDV-gC virus. This 
observed variation could be partly attributed to the inability of the rabbit anti-ILTV gC 
antisera to detect conformational epitopes of gC protein in immunofluorescence analysis. 
 
Figure 8. Western blot analysis of the rNDV’s expressing ILTV gB, gC and gD proteins. 
A: 1&4- ILTV control, 2-rNDV-gBPmeI DF1 lysate, 3-rNDV Lasota control, 5-rNDV-
gB purified virus, 6-rNDV Lasota purified virus. B:1&4- ILTV control, 2-rNDV-gC DF1 
lysate, 3-rNDV Lasota DF1 lysate, 5-rNDV-gC purified virus, 6-rNDV Lasota purified 
virus. C: 1&4- ILTV control, 2-rNDV-gD DF1 lysate, 3-rNDV Lasota DF1 lysate, 5-







Figure 8. Western blot analysis of the rNDV’s expressing ILTV gB, gC and gD proteins.  
Figure 9. Immunofluorescence analysis (Immunofluorescence analysis of vero cells 
infected with rNDV, rNDV-gB and rNDV-gD for intracellular expression and surface 
expression of ILTV proteins. Vero cells were infected with rNDV (panel B, D, F, and H), 
rNDV-gB (panel A and C) and rNDV-gD (panel E and G) and probed with rabbit anti-
ILTV gB antibodies (panel A, B, C, and D) and rabbit anti-ILTV gD antibodies (panel E, 
F, G, and H) for intracellular antigen ( panel A, B, E, and F) as well as surface expression 










4.2.4 Biological characterization of rNDV’s expressing ILTV glycoproteins 
The multicycle growth kinetics of rNDV’s expressing ILTV glycoproteins were 
compared with those of the parental rNDV. Our results demonstrated similar kinetics of 
growth between rNDV and rNDV-gC and rNDV-gD, whereas rNDV-gB grew more 
slowly and achieved a maximal titer that was approximately one log lower than those of 
parental rNDV titers (Figure 10). Similar plaque sizes were observed for rNDV and 
rNDV-gC and rNDV-gD, but a slightly smaller plaque size was observed for rNDV-gB 
(Figure 11). The pathogenicities of parental rNDV, rNDV-gB, rNDV-gC and rNDV-gD 
were evaluated by the mean death time (MDT) test in embryonated chicken eggs. The 
MDTs for these viruses is shown in Table 3. The result of Mean death time test indicates 
that the addition of ILTV genes did not increase thvirulence of NDV strain LaSota 
vector.  Indeed, the presence of the added ILTV genes conferred attenuation to the NDV 
vector. 
 





Figure 10. Growth kinetics of rNDV’s expressing ILTV gB, gC and gD proteins. 
4.2.5 Conclusions 
In the present study, we successfully recovered rNDV’s containing ILTV genes 
using reverse genetics system available in our laboratory. The expression of ILTV 
glycoproteins by recombinant viruses is confirmed by western blot analysis using DF-1 
cells and Immunofluorescence using vero cells. The ILTV glycoprotein C (gC) was 
found to be incorporated into the envelope of recombinant virus. The recombinant viruses 
were able to replicate invitro in DF-1 cells as it was determined by multi-cycle growth 
kinetics. The result of Mean death time test indicates that the addition of ILTV genes did 
not increase the virulence of NDV strain LaSota vector.  Finally, the genetic stability of 
rNDV’s containing ILTV glycoprotein genes was evaluted by 10 serial passages in 9- 
day old SPF eggs and 10 serial passages in DF-1 cells followed by sequencing analysis 














4.3 Evaluation of immunogenicity and protective efficacy of recombinant NDVs 
expressing ILTV glycoproteins in chickens. 
4.3.1 Immunogenicity and protective efficacy of rNDV’s in chickens against highly-
virulent NDV challenge 
To evaluate protective efficacy, groups of chickens were inoculated by the 
oculonasal route with rNDV LaSota, or with the recombinant rNDV’s expressing ILTV 
glycoproteins according to the protocol described in Table 4. The birds were challenged 
21 days later by the oculonasal route with highly-virulent NDV strain Texas-GB. All of 
the chickens that had been immunized with rNDV LaSot  or rNDV’s expressing ILTV 
glycoproteins were completely protected from NDV challenge without any disease signs 
and with no evidence of challenge virus replication in the organs collected 3 days post 
challenge. In contrast, all of the chickens in the unvaccinated control group and CEO 
vaccinated group died within 3 days after challenge. Each of the recombinant NDV 
immunizations induced a substantial titer of NDV-specific HI serum antibodies when 
assayed on day 21 prior to challenge. However, the mean antibody titers induced by 
rNDV’s expressing ILTV glycoproteins were approximately one or two log2 less than 
that of rNDV LaSota vaccine (Figure 12). This modest r duction in immune response to 
the vector might reflect increased attenuation of the rNDV associated with the insertion 
of the foreign gene, as indicated above by the MDT assay. The result of this study also 
suggests that expression of the ILTV glycoprotein do not interferes with protective 






Figure 12. NDV-specific serum antibody response in chickens against rNDV’s. NDV- 
specific serum antibody responses in chickens at 21 days following oculonasal 
immunization with the indicated rNDVs administered in ividually or in combination. All 
antibody titers are expressed as mean reciprocal log2 titer ± SEM (standard error of the 
mean), and the sample titers above the dotted line wer  considered positive. Statistical 
differences were calculated by one-way ANOVA with P < 0.0001. 
 
4.3.2 Immunogenicity and protective efficacy of rNDV’s in chickens against virulent 
USDA strain of ILTV challenge 
4.3.2.1 Clinical signs score evaluation 
Total clinical sign scores were recorded daily per group and are summarized in 
Figure 13a and Figure 13b. In figure 13a, total clini al scores of rNDV LaSota, rNDV-
gB, rNDV-gC, rNDV-gD vaccinated groups were compared with clinical scores of 




scores of rNDV-gB+rNDV-gC, rNDV-gB+rNDV-gD, rNDV-gC+rNDV-gD and rNDV-
gB+rNDV-gC+rNDV-gD vaccinated groups were compared with clinical scores of 
Trachivax CEO vaccinated and unvaccinated groups. Group of chickens in the control 
group and rNDV LaSota vaccinated group showed severe dyspnea with open mouth 
breathing, severe depression and severe conjunctivitis with closure of eyes between 2 to 9 
d.p.i. with 3 mortalities in each group. Birds in the control group showed symptoms of 
the disease until 11th day post challenge. As expected, birds vaccinated with the 
Trachivax CEO vaccine did not show any signs of the disease except for very mild 
depression between 2nd and 3rd day post challenge. No mortalities were observed in 
Trachivax vaccinated birds. Birds vaccinated with rNDV-gB vaccine showed severe 
signs of dyspnea, depression and conjunctivitis betwe n 2nd and 4th day post challenge 
with two mortalities recorded on 4th d.p.i. Disease signs were almost disappeared on day 
6th post challenge for rNDV-gB vaccinated group. Birds vaccinated with rNDV-gC 
vaccine showed severe disease signs between 2nd and 6th d.p.i with a single mortality 
observed on 4th d.p.i. and disease signs were record d until 8th day post infection. Birds 
vaccinated with rNDV-gD vaccine showed severe signs of disease between 3rd and 6th 
d.p.i. with two mortalities observed on 4th and 6thd.p.i. Disease signs were recorded 
until 8th day post infection for rNDV-gD vaccinated group. Birds vaccinated with 
multivalent vaccines containing rNDV’s in various combinations (Figure b) showed 
severe signs of disease on 3rd and 4th d.p.i. with no evident clinical signs observed on 
day 6th post challenge. Group of chickens vaccinated with rNDV-gB+rNDV-gD vaccine 
showed one mortality and rNDV-gC+rNDV-gD vaccinated group showed 2 mortalities 




gD vaccinated groups. Statistical analysis of clinial signs scores between groups was 
precluded because scores were recorded as a group-level measurement, rather than 
measurement on individual birds per group. 
 
 
Figure 13a. Total clinical sign scores recorded daily for rNDV LaSota, rNDV-gB, rNDV-
gC, and rNDV-gD vaccinated groups and compared with clinical scores recorded for 









Figure 13b. Total clinical sign scores recorded daily for rNDV LaSota, rNDV-gB+rNDV-
gC, rNDV-gB+rNDV-gD, and rNDV-gB+rNDV-gC+rNDV-gD vaccinated groups and 
compared with clinical scores recorded for control and Trachivax vaccinated groups. 
4.3.2.2 ILTV loads in trachea post challenge 
Viral load levels in the trachea were quantified at 4th day post challenge by 
TCID50 method and are presented in Table.6. There were no significant differences 
observed in viral load levels in the trachea between control group and rNDV’s vaccinated 
group except for the group of chickens vaccinated with rNDV-gB+rNDV-gC vaccine 
which showed approximately 2 log10 lower (P < 0.05) viral load in trachea compared to 
control group. We were not able detect challenge virus n the tracheas of Trachivax 




Group Mean tracheal viral load at 4 day post 
challenge(log10) for the indicated groups 
Trachivax 0.0 
Control 5.5 (±0.1155) 
rNDV LaSota 5.5 (±0.05773) 
rNDV-gB 5.2 (±0.5774) 
rNDV-gC 4.9 (±0.6557) 
rNDV-gD 5.5 (±0.0) 
rNDV-gB+rNDV-gC 3.7 (±1.258) 
rNDV-gB+rNDV-gD 4.7 (±1.443) 
rNDV-gC+rNDV-gD 4.7 (±1.193) 
rNDV-gB+rNDV-gC+rNDV-gD 3.2 (±1.258)  
 








4.3.2.3 Macroscopic changes in the trachea following ILTV challenge. 
The tracheas collected from the experimental chickens following ILTV challenge 
were cut open longitudinally and observed for the macroscopic lesions.  The tracheas 
collected from the chickens vaccinated with rNDV’s and control birds showed severe 
hemorrhages throughout the trachea with bloody mucus discharge, whereas  tracheas 
collected from the birds vaccinated with rNDV-gB+rNDV-gC+rNDV-gD vaccine 
showed mild lesions with only mucus discharge (Figure 14). As expected, tracheas 
collected from the Trachivax vaccinated birds did not show any lesions in the trachea 
which was correlated with the absence of challenge virus replication in trachea. 
 
 
4.3.2.4 Amplification of TK gene from the DNA isolated from trigeminal ganglia. 
DNA was isolated from the trigeminal ganglia of the birds collected 4 day post 
challenge using Qiagen’s QIAamp DNA mini kit (250) according to the manufacturer 
protocols. The isolated DNA was used to amplify TK gene by nested PCR using the 
primers mentioned in the Table 5. We were not able to amplify the TK gene from the 
DNA isolated from trigeminal ganglia of any of the experimental birds (data not shown) 









Figure 14. Macroscopic lesions in the trachea colleted from birds 4th day post challenge. 
Panel A: Trachea from the CEO vaccine Trachivax vaccinated bird, Panel B: Trachea 
from the control bird (only control bird trachea is represented here since the lesions in the 
trachea from rNDV’s vaccinated birds were similar to lesions seen in control bird 




4.3.2.5 ILTV ELISA and virus neutralizing antibody titers. 
The ILTV antibody response in pre-challenge and post-challenge sera was 
measured by ELISA and VN assay. The mean antibody titers in pre-challenge and post-
challenge sera collected from vaccinated groups wasdetermined by ELISA and is 
summarized in the Figure 15. Except for the Trachivax, rNDV-gC, rNDV-gB+rNDV-gC 
and rNDV-gB+rNDV-gC+rNDV-gD vaccinated groups; all the remaining serum samples 
were negative by ELISA for ILTV antibodies when the s rum was assayed according to 
manufacturer protocols with the test serum dilution f 1:50. However, anti-ILTV 
antibodies were detected in the pre-challenge sera collected from rNDV’s vaccinated 
birds when 1:10 dilution of test serum was used for ELISA. Post-challenge sera showed a 
mean ILTV antibody titer that ranged from 2000-7000 for rNDV’s vaccinated groups and 
a mean titer of 13500 for Trachivax vaccinated group. ELISA titers for serum samples 
collected from the control group of chickens showed a mean titer of 1000 at 14 day post 
challenge. ILTV neutralizing antibodies were also determined in serum samples collected 
from the pre-challenge and post-challenge (Figure 16). Low virus neutralizing antibodies 
were detected in the pre-challenge sera with mean titers ranging from 2-4 (log2) for all 
the vaccinated groups. Post- challenge serum samples showed a mean virus neutralizing 
antibody titers ranging from 4 to 8 (log2) for rNDV’s vaccinated birds and surprisingly, 
the neutralizing antibody titers in the post challeng  sera from Trachivax vaccinated birds 
were of low titer in the range of 1-2 (log2) and such titers were not different from the 








Figure 15. ILTV antibody titers determined by ELISA on serum samples collected pre-
challenge and post-challenge. A: Pre-challenge ILTV antibody titer when 1:10 dilution of 
test serum used, B: Pre- challenge ILTV antibody titer when 1:50 dilution of test serum 






Figure 16. . ILTV antibody titers determined by VN assay on serum samples collected 
pre-challenge and post-challenge. A: Pre-challenge ILTV antibody titer and, B: Post-






Currently  gB  is  the  only  ILTV  glycoprotein  whose  role  has  been  evaluated  
in protective  immunity [22]. However, the role of other ILTV glycoproteins in protection 
and immunity has not been studied. Therefore, a virulent challenge study was carried out 
in chickens to evaluate the individual contributions of ILTV gB, gC, and gD surface 
proteins to the induction of neutralizing antibodies and protective immunity. It is possible 
that more than one ILTV glycoprotein is essential for induction of complete protective 
immunity. Therefore, we have also evaluated these thr e glycoproteins in all possible 
combinations via multivalent vaccine strategy consisting of a mixture of rNDVs each 
carrying different genes (gB, gC and gD) of ILTV. A single oculonasal inoculation of 
chickens with rNDV’s expressing ILTV glycoproteins elicited detectable level of 
systemic antibodies specific to expressed ILTV glycoproteins with the response to 
rNDV-gC being higher than those to rNDV-gB or rNDV-gD. Following challenge with 
virulent USDA challenge strain of ILTV, chickens immunized with the recombinant 
NDV’s displayed partial protection with reduced clinical signs and shorter duration of 
disease compared to control group. The rNDV vectored vaccines fails to prevent the 
challenge virus replication in trachea following challenge with USDA strain of ILTV. 
However, chickens immunized with the multivalent vaccine consisting of rNDV-gB, 
rNDV-gC and rNDV-gD viruses exhibited reduced challenge virus replication in trachea 
compared to control birds. Following challenge, the titers of serum antibodies specific to 
ILTV glycoproteins were higher in the animals immunized with the rNDV vaccines 
compared to the rNDV parent virus, indicating that the vaccines primed for secondary 




infection, but might require augmentation by a second dose or require modification of 
ILTV glycoproteins which allow them to incorporate into the mature rNDV virions for 
better induction of humoral and CMI response. Further, the results of the present study 
strongly suggests that the multivalent vaccines consisti g of rNDV’s expressing ILTV 
gB, gC and gD is very effective in clearing the infection in an accelerated time frame and 
also reduced the challenge virus replication in trache  and mitigated the clinical signs of 
















Chapter 5: Discussion 
ILT is a highly contagious disease of chickens worldwide. The disease causes 
significant economic  losses  due  to  morbidity,  mortality,  decreased  egg  production,  
weight  loss, and predisposition to other avian pathogens [1, 46]. Traditionally, ILTV is 
controlled by the use of modified‐live vaccines.  However, current   modified‐live ILTV 
vaccines have a number of disadvantages including insufficient attenuation, production of 
latently infected carriers, and increased virulence as a result of bird‐to‐bird passage (2, 3, 
4). Therefore, there is a need to develop alternative vaccine strategies for ILT which can 
be used in both layers and broilers. Among the possible strategies, one of the most 
promising is the use of live viral vectored vaccines. The major advantage of a live viral 
vectored vaccine is that they do not require the use of the whole infectious pathogen but 
can have the efficacy of live-attenuated vaccine. Sveral studies conducted to date 
suggest that a virus‐vectored ILTV vaccine will be most effective for prevention and 
control of ILT. A vectored‐vaccine will be safe and not lead to reversion to virulence or 
establishment of latency (22, 58). Several viruses uch as fowlpox, adenovirus, 
adeno‐associated virus, NDV and HVT are available for usea  vaccine vectors. But each 
viral vector has its own advantages and disadvantages for use as a vaccine vector for 
ILTV.  NDV has a several feature that make it a promising viral vector for ILTV vaccine. 
Avirulent NDV strains have been widely used as vaccines for more than 50 years with a 
proven record of safety and efficacy.  NDV is a respiratory pathogen and efficiently 
induces mucosal immunity at the respiratory tract, which is also the site of replication for 
ILTV. NDV induces strong systemic IgG antibody and CMI responses [15]. NDV is a 




immune competition between engineered ILTV antigen and NDV‐specific antigens. A 
NDV‐vectored ILTV vaccine can be used as early as one day of age; therefore, it can be 
used in broiler chickens. NDV‐vectored vaccines can be administered by spray or in 
drinking water, which will allow vaccination of a lrge number of birds in a short time. 
Chickens in the United States are routinely vaccinated with live‐attenuated NDV vaccine. 
Therefore,   NDV‐vectored  ILTV  vaccine  will  be  a  bivalent  vaccine  and  will  not  
require introduction of a new  vaccine.  Another advantage of the NDV‐vectored ILTV 
vaccine is that vaccinated chickens can be distinguished from naturally ILTV infected 
ones by serological tests. Therefore, development of an NDV‐vectored ILTV vaccine will 
be highly beneficial to the poultry industry in the United States. In this study, for the first 
time, we have evaluated the potential of NDV as a vir l ector for ILTV vaccine. 
   ILTV infection predominantly affects the mucosa and submucosa of the upper 
respiratory tract of chickens and leads to the induction of both mucosal and systemic 
immune response (49, 50). ILTV has eleven envelope glycoproteins and gB has been 
shown to be a major protective immunogen [22], but the roles of gC and gD in immunity 
and protection have not been determined. In the present study, we have investigated the 
individual contributions of three important envelope glycoproteins of ILTV (gB, gC, and 
gD) in protection and immunity.   
 A single oculonasal inoculation of chickens with rNDV’s expressing ILTV 
glycoproteins elicited detectable level of systemic antibodies specific to expressed ILTV 
glycoproteins with the response to rNDV-gC being hiher than those to rNDV-gB or 
rNDV-gD. The immune response produced by a single immunization with these rNDV’s 




replication in trachea, but reduced the mortality, severity and the duration of  disease 
compared to the control group. The increase of ILTV specific antibody titers in 
vaccinated chickens following challenge suggested that vaccine primed for secondary 
response. Detection of antibodies against expressed ILTV glycoproteins was not 
interpreted as a measure of protection, but rather as a measure of antigenicity of ILTV 
glycoproteins expressed by the vector. However, the presence of low titers of ILTV 
specific antibodies in the pre-challenge sera coincided with the presence of clinical signs 
and high level of challenge virus in the trachea. On the other hand, the presence of higher 
titers of ILTV antibodies in the pre-challenge sera collected from rNDV-gB+rNDV-gC 
and rNDV-gB+rNDV-gC+rNDV-gD immunized birds coincide  with the reduced 
challenge virus replication in trachea and reduced  mortality, severity and duration of the 
disease. Although direct evidence of major effector mechanisms involved in ILTV 
immune response is lacking, it has been documented that humoral antibody response by 
itself does not provide the immunity necessary for protection against ILTV infections 
(50, 51, 87, 88). The minor role that antibodies play in immunity against ILTV infections 
is further confirmed by the absence of measurable lev ls of neutralizing antibodies in the 
sera collected from CEO vaccinated birds. Therefore, to thoroughly assess the 
immunogenicity and protective efficacy of rNDV vectored ILTV vaccines, the mucosal 
and cell-mediated immunity would need to be evaluated.  
In the present study, the failure to provide complete protection against ILTV by 
the rNDV’s expressing ILTV glycoproteins likely was due to insufficient induction of 
systemic immune response.  Previous studies have also reported varying degree of 




There could be many reasons for the partial protecti n conferred by NDV vectored ILTV 
vaccines in this study. First, it is possible that repetitive doses of the rNDV’s expressing 
ILTV proteins are necessary to augment the systemic i mune response for complete 
protection. Second, in the present study, only ILTV-gC is found to be incorporated into 
the mature rNDV virion which leads to the better antigen presentation and hence 
induction of humoral immune response in chickens immunized with rNDV-gC vaccine 
compared to rNDV-gB or rNDV-gD vaccine. Therefore, ILTV gB and gD glycoproteins 
require certain modifications which allow them to incorporate into the mature rNDV 
virions for better induction of humoral response and therefore better CMI response. 
Third, in this experiment chickens were challenged with a high dose of virulent USDA 
challenge strain of ILTV. Such a high dose of infections does not occur under natural 
conditions. Hence overwhelming the immune response by challenge virus exists. 
In future directions, the following strategies can be employed to further improve 
the rNDV based ILTV vaccines. First of all, in the current study only ILTV gC was found 
to be incorporated into the mature rNDV virion and rNDV expressing ILTV gC can 
readily activate the antigen presenting cells and B-cells for the better induction of 
humoral response which is coincided with the better antibody response to rNDV-gC 
compared to rNDV-gB or rNDV-gD. Also, induced antibodies can have an opsonizing 
ability to further improve the cell mediated immune responses. Therefore, ILTV gB and 
gD proteins requires certain modification that allow them to incorporate into the mature 
rNDV virion. To achieve this, one of the most promising strategy is to fuse the 
ectodomain of ILTV gB and ILTV gD proteins to transmembrane and cytoplasmic tail of 




strategy is very straightforward and has been demonstrated to be very useful in enhancing 
the incorporation of foreign proteins into envelope of mature rNDV’s (13). Further, 
Immune response to mature rNDV envelope incorporated ILTV proteins can be improved 
by use of repetitive doses of vaccines and also by use of killed vaccines to minimize the 
immune competition between ILTV proteins and NDV env lope proteins. Secondly, it 
might necessitate the inclusion of additional ILTV antigens for complete protection. It is 
known that ILTV   glycoproteins   have homologous glycoproteins in other herpesviruses 
and It has been shown that in  herpes  simplex virus (HSV) gB, gC, gD, gE and gI 
induced highest neutralizing  titers  and  protective  immunity  [6].  Therefore, the 
incomplete protection generated by vaccination with NDV vectors expressing only gB, 
gC and gD might be overcome by simultaneously administering NDV vectors expressing 
the gB, gC, gD, gE and gI proteins. 
In summary, for the first time we have evaluated the potential of rNDV as a viral 
vector for ILTV vaccine. Our results showed that chickens immunized with recombinant 
viruses elicited an immune response against ILTV proteins and provided partial 
protection against virulent ILTV challenge. These results suggested that ILTV envelope 
glycoproteins gB, gC and gD could be a useful components of live viral vectored 
vaccines for ILTV infection. Furthermore, this strategy may be useful for the 
development of live viral vectored vaccines against ILT for which currently safe and 
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